Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company specializing in the development, production, and commercialization of innovative bioprocessing technologies and systems that enhance the efficiency of biological drug manufacturing. Headquartered in Waltham, Massachusetts, the company operates additional manufacturing facilities in Sweden, Estonia, France, Germany, Ireland, the Netherlands, and the United States.
Repligen is renowned for its high-quality bioprocessing products, which are essential in the production of biological drugs. The company's product portfolio includes Protein A, a critical reagent used in the manufacturing of monoclonal antibody-based therapeutics, and several growth factor products that boost cell culture productivity in biomanufacturing. Additionally, Repligen offers OPUS™ (Open Platform User Specified) single-use chromatography columns, which are pivotal in the biologics purification process.
The company serves a diverse customer base that includes major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide. Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, complemented by strategic partnerships in select regions. North America remains the primary market, contributing the majority of the company's revenue.
Recent achievements include the acquisition of Metenova AB, a leading innovator in magnetic mixing technologies, to expand its Fluid Management portfolio. Despite challenges in the bioprocessing market, Repligen continues to exhibit resilience with steady revenue growth, particularly in its Analytics and Chromatography franchises.
Financially, Repligen reported second quarter revenues of $159.2 million in 2023 and has adjusted its full-year revenue guidance to a range of $635-$665 million. The company remains optimistic about overcoming current market headwinds, with a growing pipeline of opportunities expected to bolster orders in the fourth quarter.
Overall, Repligen's commitment to bioprocessing technology leadership and continuous innovation positions it as a significant player in the life sciences industry, driving advancements that support the development of life-saving biological drugs.
Repligen (RGEN) reported Q3 2024 financial results with revenue of $155 million, up 10% year-over-year. CDMO and equipment revenues grew approximately 20% and 6% respectively. The company achieved record quarterly revenue for new modalities, increasing 20% year-over-year. Full-year 2024 revenue guidance was narrowed to $630-$639 million. Q3 adjusted earnings per share was $0.43, compared to $0.23 in Q3 2023. The company announced plans to acquire Tantti Laboratory to support its Proteins and Chromatography franchises.
Repligen (NASDAQ:RGEN) has announced its participation in three major investor conferences in November 2024. The company will present at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 14, the Stifel Healthcare Conference in New York City on November 19, and the Stephens Annual Investment Conference in Nashville on November 20.
CFO Jason Garland and CEO Olivier Loeillot will participate in analyst-led discussions at these events. All presentations will be available via live webcast through Repligen's Investor Relations website, with -time replay access after the events.
Repligen (NASDAQ:RGEN) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, before market open, followed by a conference call at 8:30 a.m. ET. CEO Olivier Loeillot mentioned that the team is working to complete previously disclosed revenue restatements from September 18. The company plans to file amended periodic reports along with the Q3 2024 results. The conference call will be accessible via toll-free numbers and webcast through the company's Investor Relations section, with replay options available using passcode 3384562.
Repligen (NASDAQ:RGEN) has announced the grand opening of its Repligen Training & Innovation Center (RTIC) at its Waltham headquarters. The 7,500 square foot facility is designed to provide customers with pre- and post-sales support and hands-on experience with Repligen's bioprocessing solutions. The RTIC features product exhibits, demonstration areas, and technical training space, showcasing Repligen's complete collection of bioprocessing technologies.
The center includes displays of upstream intensification technologies, downstream products, and integrated systems. It also highlights process analytics technologies and fluid management products. The RTIC aims to elevate customer experience through live engagement with subject matter experts and demonstrate Repligen's end-to-end capabilities.
In addition to the RTIC, Repligen has expanded its Waltham site to a total of 182,000 square feet and completed a site relocation and expansion in Jüri, Estonia, earlier this year. The Estonian facility is an 80,000 square foot, LEED Silver certified Customer Center of Excellence for advanced TFF and chromatography systems.
Repligen (NASDAQ:RGEN), a leading bioprocessing technology company in the life sciences sector, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The event is scheduled to take place from September 4-6 in Boston.
Olivier Loeillot, Repligen's President and CEO, will engage in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Repligen's Investor Relations website at www.repligen.com. The replay of the presentation will be available for a time after the event.
This conference provides Repligen with an opportunity to showcase its latest developments and strategic initiatives in the bioprocessing technology field to investors and industry analysts.
Repligen (NASDAQ:RGEN) reported its Q2 2024 financial results, with revenue of $154 million and orders of $157 million. The company achieved a book-to-bill ratio of 1.02 for the quarter and 1.01 year-to-date. Repligen narrowed its revenue guidance within the previous range for fiscal year 2024, while maintaining its adjusted EPS guidance. Key highlights include:
- Solid Q2 revenue and first half revenue of $305 million
- Strong Pharma demand and increased CDMO activity
- Continued momentum in new modalities
- Announced CEO transition and pending acquisition of Tantti Laboratory
- Adjusted earnings per share of $0.33 on a fully diluted basis
The company expects the second half of 2024 to outpace the first half in both revenue and orders, despite some weakness in China.
Repligen (NASDAQ:RGEN) has announced an agreement to acquire Tantti Laboratory Inc., a privately-held company based in Taiwan. Tantti specializes in macroporous chromatography beads for purifying new modalities like viral vectors, viruses, and nucleic acids. The acquisition aims to enhance Repligen's bioprocessing technology portfolio, particularly in the new modality space.
Key highlights of the deal include:
- Integration of Tantti's DuloCore® technology with Repligen's AVIPure® affinity ligands and OPUS® pre-packed chromatography columns
- Expected completion in Q4 2024, subject to regulatory approvals
- Anticipated to be breakeven on adjusted margins and EPS in 2025, becoming accretive in 2026
This strategic move is set to address downstream bottleneck challenges and scalability concerns in bioprocessing, potentially establishing DuloCore as a gold standard for new modality purification.
Repligen (NASDAQ:RGEN) has announced that it will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The company will issue a press release before the market opens and host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six-month periods ended June 30, 2024.
Investors can access the conference call by dialing (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. A webcast will also be available via the Investor Relations section of Repligen's website. Both the call and webcast will be archived for future access, with replay dial-in numbers provided for U.S., Canadian, and international callers.
Repligen (NASDAQ:RGEN) announced a leadership transition plan where Tony J. Hunt will move from CEO to Executive Chair, and Olivier Loeillot will become President and CEO, effective September 1, 2024. Hunt has been CEO since May 2015, leading the company to significant growth, including an increase in revenue from $63 million in 2014 to $639 million in 2023. Loeillot, who joined Repligen in October 2023, brings nearly 30 years of industry experience, including leadership roles at Cytiva and GE Healthcare Life Sciences. Current Board Chair Karen A. Dawes will become Lead Independent Director.
Ecolab, in partnership with Repligen , announced the commercial launch of DurA Cycle Affinity Resin, designed for large-scale purification in biologic manufacturing. This product, launched at BIO 2024 in San Diego, targets efficient monoclonal antibody production, reducing costs for biologic drug developers. The launch reflects Ecolab's ongoing commitment to bioprocessing innovations, following two other resins launched in the past eighteen months. The partnership aims to address complex challenges in biologic manufacturing and is bolstered by Ecolab's investment in a new production facility in Landenberg, PA, complementing its UK-based facility.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
What does Repligen Corporation specialize in?
Where is Repligen's headquarters located?
What are some key products offered by Repligen?
Who are Repligen's primary customers?
How does Repligen market its products?
What recent acquisition has Repligen made?
What was Repligen's revenue for the second quarter of 2023?
What is Repligen's revenue guidance for the year 2023?
Which regions contribute the most to Repligen's revenue?
What is Repligen's focus area?
